跳至主要内容
临床试验/NCT04454983
NCT04454983已完成不适用

Lipiflow vs iLux Patient Acceptance and Comfort Study

Epstein, Arthur B., OD, FAAO2 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2020年1月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
43
试验地点
2
主要终点
Procedure Comfort

研究概览

简要总结

This study was designed to compare patient acceptance, comfort, and preference between two meibomian gland clearing devices (Lipiflow vs, iLux). Primary Objective was to compare patient comfort as assessed by Likert-style scale questionnaire following each bilateral procedure. Secondary Objective was to compare overall experience and treatment preference as assessed by Likert-style questionnaire following each bilateral procedure. Both devices are exempt from IDE regulations [21 CFR 812.2(c)].

详细描述

Introduction Meibomian gland disease (MGD) is increasingly recognized as a primary cause or contributor to tear instability and dry eye disease. Effective management of this disorder often requires meibomian gland expression and clearance. A variety of devices which apply pressure, heat or a combination of both to the glands have been used.

Two such devices that apply heat and pressure simultaneously are commercially available. LipiFlow (JNJ Vision Care) is an automated computer-controlled device that uses vectored thermal (hydraulic) pulsation applied by an activator device placed on the eye between the globe and the eyelids to achieve gland clearance. The iLux System (Alcon) is an operator controlled assisted manual device which applies heat generated by infrared LEDs and expression through cam driven mechanical pressure applied to the lids.

Device Descriptions LipiFlow Thermal Pulsation System

The Lipiflow Thermal Pulsation System is a commercially available device used in the treatment of MGD. It is cleared to be marketed by the United States Food and Drug Administration. The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye.

The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements. The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland. Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid, without damaging the eyelid or delicate structures of the globe. Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages. Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ (VTP) technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content. Vectored heat and adaptive force equalization target the pulse, heat, and pressure on the meibomian glands to maximize effectiveness. Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject can be of any gender or race
  • Subject must be 18 years of age or older at the time of informed consent
  • Subject must be able to understand and must sign an Informed Consent that has been approved by an IRB
  • Subject must have confirmed diagnosis of Meibomian Gland Dysfunction
  • Subject must agree to not wear contact lenses the day of the Study visit

排除标准

  • History of intraocular or oculoplastic surgery within 6 months of Screening visit
  • History of ocular injury or trauma, chemical burns, or limbal stem cell deficiency within 3 months of the Screening visit
  • Active ocular infection or active ocular inflammation (including allergic conjunctivitis, vernal or giant papillary conjunctivitis) at time of Screening visit
  • History of ocular surface abnormality that may compromise corneal integrity
  • History of treatment with LipiFlow or iLux in either eye in the last 6 months
  • Allergy to topical proparacaine eye drops

结局指标

主要结局

Procedure Comfort

时间窗: 5 minutes

Likert-scale questionnaire: 1=strongly disagree, 2=disagree, 3=Undecided, 4=Agree, 5=strongly agree - 1 Question

次要结局

  • Patient Preference(5 minutes)
  • Procedure Experience(5 minutes)

研究者

发起方
Epstein, Arthur B., OD, FAAO
申办方类型
Indiv
责任方
Principal Investigator
主要研究者

Dr. Arthur Epstein

Director of Dry Eye and Ocular Surface Disease

Epstein, Arthur B., OD, FAAO

研究点 (2)

Loading locations...

相似试验